Human placental proteomics and exon variant studies link AAT/SERPINA1 with spontaneous preterm birth

Heli Tiensuu1,2†, Antti M. Haapalainen1,2†, Pinja Tissarinen1,2, Anu Pasanen1,2, Tomi A. Määttä1,2, Johanna M. Huusko1,2,3, Steffen Ohlmeier4, Ulrich Bergmann4, Marja Ojaniemi1,2, Louis J. Muglia3,5, Mikko Hallman1,2† and Mika Rämet1,2,6*†

Abstract

Background: Preterm birth is defined as live birth before 37 completed weeks of gestation [1]. Currently, we have an incomplete understanding of the factors that lead to PTB. Both maternal and fetal genomes are likely involved in the timing of birth, as well as in the onset of spontaneous preterm deliveries. Protein and mRNA levels of alpha-1 antitrypsin/SERPINA1 from the maternal side of the placenta were downregulated in spontaneous preterm births. Alpha-1 antitrypsin was expressed by villous trophoblasts in the placenta, and immunoelectron microscopy showed localization in decidual fibrinoid deposits in association with specific extracellular proteins. siRNA knockdown in trophoblast-derived HTR8/SVneo cells revealed that SERPINA1 had a marked effect on regulation of the actin cytoskeleton pathway, Slit–Robo signaling, and extracellular matrix organization.

Conclusions: Alpha-1 antitrypsin is a protease inhibitor. We propose that loss of the protease inhibition effects of alpha-1 antitrypsin renders structures critical to maintaining pregnancy susceptible to proteases and inflammatory activation. This may lead to spontaneous premature birth.

Keywords: Alpha-1-antitrypsin, Placenta, Proteomics, Preterm birth, SERPINA1, Trophoblast, Whole exome sequencing

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
PTB (SPTB) [2–4]. Several pathological processes that involve inflammation, infection, endocrine events, disorders in blood clotting, or uterine distention may activate labor before term [5].

It is challenging to evaluate and predict the risk of preterm delivery because there is a lack of accurate biomarkers and an incomplete knowledge of the pathophysiology of SPTB [6]. Several biological specimens (e.g., cervical fluid, amniotic fluid, and maternal blood) have been studied to identify SPTB-associated risk factors and pathways and biomarkers associated with adverse pregnancy outcomes [1, 6–9]. Elevated levels of fetal fibronectin (fFN) measured from cervicovaginal fluids may predict a higher risk of preterm delivery [7, 10, 11]. However, the results are inconsistent and suggest that the predictive power of fFN has somewhat low sensitivity and specificity [7, 12]. Activation of inflammatory pathways and the complement system are proposed to be involved in the pathogenesis of SPTB [6–8, 13]. Interleukins, such as IL-6 and IL-8, have been observed to be elevated in the sera or cervicovaginal fluids of mothers who gave birth preterm [7, 13], but their predictive power is limited. Despite the research described above, currently there is no efficient and reliable predictive test for preterm birth [6–8].

The placenta is a multifunctional organ involved in fetal oxygen and nutrient uptake, as well as metabolism, immune defense function, and the elimination of toxic products [14]. In addition, placental components, compartments, and fetal membranes may be involved in regulation of the duration of pregnancy and onset of human labor [15]. Proteomic analyses of human placenta have mostly focused on pathological conditions such as preeclampsia [16] and fetal growth restriction [17]. Few placental proteomic studies have focused on term labor [18] and none have focused on preterm labor. According to a study by Heywood et al., the proteome varies among different parts of the placenta [19]. The fetal side of the placenta expresses proteins in pathways associated with actin arrangement, contraction, implantation, and negative regulation of peptidases, while the sub-proteome on the maternal side is more involved in antigen presentation, energy metabolism, and protein folding [19]. Another study compared proteome differences in the human placenta between the first and third trimesters and identified 11 differentially expressed proteins [20]. Levels of four proteins—protein disulfide isomerase, tropomyosin 4 isoform 2, enolase 1, and heat shock protein A5—decreased toward term, and seven proteins—actin γ1 propeptide, heat shock protein gp96, alpha-1 antitrypsin, EF-hand domain family member D1, tubulin α1, glutathione S-transferase, and vitamin D-binding protein—increased from the first trimester to the third trimester [20].

Abnormal levels of various SERPINs are associated with pregnancy complications [21–24]. The human genome contains 36 serine protease inhibitor (SERPIN)–coding genes, which are divided into nine clades (A–I) [25]. SERPINs regulate various pathways such as blood coagulation, fibrinolysis, and inflammation [26]. Clade A (SERPINA) is the largest group, and members of clade A are antitrypsin-like extracellular proteins [25]. SERPINA1 encodes alpha-1 antitrypsin (AAT), a 52-kDa single-chain glycoprotein [27] involved in inhibition of serine proteases such as neutrophil elastase, trypsin, chymotrypsin, and plasminogen activator [28, 29]. Neutrophil elastase in cervical secretions has been proposed to predict premature delivery [30]. In addition to protease inhibition, SERPINA1 family members prevent collagen breakdown, which triggers hypoxia [31]. Low serum levels of AAT are associated with spontaneous abortion and elevated proinflammatory cytokines [21], and SERPINA3 is a potential preeclampsia marker [22]. Additionally, higher maternal serum levels of SERPINB7 are associated with SPTB [23]. Moreover, SERPINE2 is found in villous and extravillous trophoblasts of the human placenta and affects trophoblast migration and invasion [24]. It has also been shown that a functional SNP in the promoter of the SERPINH1 gene significantly reduced promoter activity in amnion fibroblast cells and thus increases risk of preterm premature rupture of membranes (PPROM), the leading cause of preterm birth [32].

The initial aim of this study was to identify placental proteins that may be associated with SPTB onset. We used a hypothesis-free approach by comparing the proteomes of human placentas from SPTB, spontaneous term birth (STB), and elective preterm birth (EPTB). After we identified protein candidates, we investigated the whole exon sequences from mothers and children of families with more than one SPTB. Our aim was to identify rare, likely damaging variants that lead to SPTB. This yielded a single candidate protein, AAT, which is encoded by SERPINA1. To explore the function of AAT/SERPINA1 in the placentas of SPTBs, we performed further experiments on placental samples and placenta-derived cells. We propose that AAT/SERPINA1 is an important resistance factor in the inflammatory, endocrine, hematologic, and proteolytic events associated with predisposition to SPTB.

**Methods**

**Study workflow**

Protein levels in the placenta vary during pregnancy, and some changes are associated with adverse pregnancy outcomes [5, 33]. To investigate placental proteins that are up- or downregulated during spontaneous preterm labor, we determined the proteomes of human placentas.
and then analyzed them with respect to spontaneous preterm birth (SPTB), elective preterm birth (EPTB), and spontaneous term birth (STB) cases. Maternal (basal plate) and fetal (chorionic plate) sides of the placenta were studied separately. SPTB and STB placentas were compared to identify protein candidates associated with gestational age, and SPTB and EPTB placentas were compared to identify proteins differently expressed in spontaneous delivery. We then compared the proteomes (SPTB vs. STB compared with SPTB vs. EPTB) to discover protein candidates associated with both short gestational age and spontaneous delivery; i.e., spontaneous preterm birth. The study workflow is presented in Fig. 1.

Placental proteomics

We used proteomics data to explore protein levels in the human placenta. Proteomics data from placental samples were generated by two-dimensional minimal-difference gel electrophoresis and mass spectrometry, as described previously [18] (Additional file: Fig S1, Tables S1–S3). In short, placental samples were obtained from SPTB (GA 25–35 weeks, \(n = 6\)), EPTB (GA 25–30 weeks, \(n = 6\)), and STB (GA 39–41 weeks, \(n = 6\)) cases. Tissue biopsies were collected from both basal and chorionic plates. In the comparison, we used a \(p\) value of < 0.05 (Student’s \(t\) test) and a 1.5-fold cut-off ratio to consider if differences in protein spots were significant and selected for further identification with mass spectrometry. We excluded samples from cases that involved induction of labor, placental abnormalities, congenital malformations, preexisting medical conditions, and multiple births.

WES data

Proteomic findings were compared with three population sets with available whole exome sequencing (WES) data. Two datasets consisted of Northern Finnish mothers with preterm deliveries (\(n = 17\)) [34] and their children (\(n = 23\)) who were born preterm (GA < 36 weeks) [35]. The third dataset was Danish WES data of European ancestry, which included 192 women from 95 families. Selection criteria for the WES analyses have been previously described in detail [36, 37], and WES was performed as previously described in detail [34]. When we compared the proteomic findings with the WES datasets, our selection criteria were rare (MAF

---

Fig. 1 Workflow of the present study. The starting point of this study was to determine proteomes from spontaneous preterm (SPTB), spontaneous term, and elective preterm human placentas to identify proteins potentially in association with SPTB. When we compared the proteomic findings with whole exome sequencing (WES) data from SPTB families, AAT/SERPINA1 emerged as a candidate. To verify our findings and to explore the location and function of AAT/SERPINA1 in placentas of SPTB, we performed experiments on placental samples and placenta-associated cells. The placenta samples on which the proteomics were performed were also included in the following analyses. Only in immuno-EM and immunofluorescence microscopy, the placenta samples were different. \(N\) is number of samples, FIN is Finland, and DK is Denmark. *Finnish WES; 17 mothers and their 23 children. Danish WES, \(n = 93\) sister pairs and two families with three affected siblings.
< 1%) or common (MAF < 10%) potentially damaging variants (categories 1–3, described previously [34]) found in at least two different families.

Western blotting of AAT
The proteomic result of AAT (P01009) was validated with quantitative western blot methodology, as described previously [18]. Tubulin α-1B was used as a reference protein to which all samples were normalized. We used mouse monoclonal anti-human AAT antibody (MA5-15521, 1:2000 dilution, Invitrogen) and rabbit monoclonal anti-human tubulin α-1B antibody (NB110-57609, 1:5000, NovusBio) to detect AAT and tubulin α-1B, respectively (Additional file: Fig S2). Quantitative western blot results were analyzed with SPSS Statistics 20.0 (IBM Corporation). The nonparametric Mann–Whitney U test was used to evaluate the level of statistical difference.

qRT-PCR of SERPINA1
To determine mRNA levels of SERPINA1 in the placenta, we conducted qRT-PCR. We included samples from the basal plate of the placenta and compared samples from SPTB (n = 18) and STB (n = 22). Samples were collected in 2010–2016 as described previously [38]. Inclusion criteria for gestational age were from 25 weeks to 36 weeks + 6 days for SPTB samples and from 39 weeks to 41 weeks + 6 days for STB samples.

Placental RNA was isolated as described previously [38]. The quality and quantity of isolated RNA was determined with a NanoDrop (Thermo Fisher) by measuring absorbance values at 230, 260, and 280 nm. Total RNA was converted into cDNA with the Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics) according to the standard qRT-PCR procedure.

A LightCycler96 instrument (Roche Diagnostics) was used to assess relative quantifications of SERPINA1. Measured mRNA levels were normalized against a reference gene, cytochrome C1 (CYC1), and relative quantifications were determined with the ΔΔ cycle threshold method. Primers and probes were designed with the Universal Probe Library (UPL) Assay Design Center (Roche). Primers and probes for SERPINA1 were forward 5′-GTG GTTTCCTGAGCCACGAG-3′ and reverse 5′-CCCCGTCTATT-3′ (UPL probe #86). Primers and probes for CYC1 were forward 5′-ATAAAGCCGAC AAGTGATGTC-3′ and reverse 5′-GATGGGCTTTGG GCTTGAGG-3′ (UPL probe #47). Each qRT-PCR measurement was done in triplicate. Statistical analysis was performed by nonparametric Mann–Whitney U test with SPSS Statistics 26.0 (IBM Corporation).

Immunohistochemical staining of AAT
Placental samples were analyzed by immunohistochemical staining to visualize the localization of AAT as described previously [39]. Samples for AAT were from six SPTB deliveries and six STB deliveries. The samples were embedded in paraffin and cut into 4-μm slices. For detection, the samples were incubated with rabbit anti-human AAT antibody (1:1000 dilution, PA5-16661, Invitrogen). Non-immune rabbit IgG was used for negative controls.

Immuno-EM of AAT and fibronectin
Immuno-EM was performed at the Biocenter Oulu Electron Microscopy Core Facility. Fresh human placenta samples were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer with 2.5% sucrose, pH 7.4 for 6 h. After fixation, samples were immersed in 2.3 M sucrose and frozen in liquid nitrogen. Thin cryosections were cut with a Leica EM UC7 cryo-ultramicrotome (Leica Microsystems). For immunolabeling, sections on Butvar-coated nickel grids were first incubated in 0.1% glycine-PBS for 10 min followed by incubation in a blocking serum containing 1% BSA in PBS for 5 min. We used 1% BSA in PBS for washing steps and dilutions of antibodies and gold conjugates. Sections were exposed to primary antibodies to AAT (1:100 dilution, PA5-16661, Invitrogen) or fibronectin (1:100 dilution, ab6328, Abcam UK) for 45 min. Rabbit anti-mouse IgG (Jackson Immunoresearch Laboratories Inc.) was used as a bridging antibody for fibronectin antibody for 30 min. Bound antibodies were labelled by incubation with protein A–conjugated 10 nm gold (Cell Microscopy Core, University Medical Center Utrecht) for 30 min. Controls were prepared by replacing the primary antibody with PBS. Grids were stained with neutral uranyl acetate (UA) and coated with 2% methyl cellulose containing 0.4% UA. Thin sections were imaged with a Tecnai G2 Spirit 120 kV transmission electron microscope (FEI Company), and images were captured by a Quemesa CCD camera (Olympus Soft Imaging Solutions GMBH).

Fluorescence colocalization analysis
Fluorescence colocalization analysis was performed with human placental tissue samples. Human placental tissue samples were treated as described previously [40]. Colocalization of the following complexes were analyzed: AAT–fibronectin, AAT–vitronectin, AAT–collagen, AAT-Rab7, and AAT-CD63.

To detect AAT, fibronectin, vitronectin, collagen IV, Rab7, and CD63, respectively, we used rabbit anti-human AAT antibody (PA5-16661, 1:250 dilution, Thermo Fisher Scientific), mouse anti-human fibronectin antibody...
Subculturing was done with 0.05% trypsin/0.02% EDTA.

C). For the control, MISSION siRNA Universal Negative Control #1 (Sigma-Aldrich) was transfected in the manner described above. ACTG1, CEACAM1, FNI, and SLIT2 were chosen from the RNA sequencing data from the SERPINA1 knockdown. Primers and probes were forward 5′-GCCAGGATCCCTAAGTCTCA-3′ and reverse 5′-GTAGAAGGAGTGGTCCAGA-3′ for ACTG1 (UPL probe #9), forward 5′-CCCATCATGCTGAACGTAAA-3′ and reverse 5′-AGGCCCACACTCCTACAC-3′ for CEACAM1 (UPL probe #57), forward 5′-GCCAGAGTCCCCCTACTACA-3′ and reverse 5′-GTCTTCAGAAGTGCTCTACTCA-3′ for FNI (UPL probe #52), and forward 5′-CTTCCAGAGCACACACAGAAA-3′ and reverse 5′-CGTCTAGAAGTCTCTACTCA-3′ for SLIT2 (UPL probe #79). Probes were from the UPL Set (Roche Diagnostics). Each qPCR measurement was done in triplicate. Levels were normalized against the CYC1 level, and relative quantifications were then assessed with the ΔΔ cycle threshold method as described previously.

Gene knockdown of SERPINA1 by transfection with siRNA
We used the human placental trophoblast cell line HTR8/SVneo (CRL-3271, ATCC) to perform gene knockdown of SERPINA1. Cells were grown in RPMI-1640 growth medium (Thermo Fisher Scientific) supplemented with 10% fetal bovine serum (Sigma-Aldrich) and 1× penicillin/streptomycin (Sigma-Aldrich) under standard culturing conditions (37 °C, 5% CO2, humidified atmosphere). Subculturing was done with 0.05% trypsin/0.02% EDTA.

HTR8/SVneo cells were reverse and forward transfected with siRNA targeting SERPINA1 (s GUCCAU UACUGGAACCUAU, a AUAGGCUCCAGUAUGGAC). For the control, MISSION siRNA Universal Negative Control #1 (Sigma-Aldrich) was transfected in the same way as siRNA targeting SERPINA1. Lipofectamine 3000 reagent (Invitrogen) was used as a transfection reagent. Cells (100,000/well) were incubated with 10 nM siRNA in the reverse transfection. Forward transfection was performed after 24 h of incubation. In the forward transfection, cells were again transfected with 10 nM siRNA concentrations. Cells were incubated with siRNA for 48 h and then harvested with 1× trypsin/EDTA (Sigma-Aldrich).

Knockdown of SERPINA1 in the silenced cells was verified by qRT-PCR according to the standard qRT-PCR procedure, as described earlier for qRT-PCR of SERPINA1. A LightCycler96 (Roche Diagnostics) was used to assess relative quantifications of SERPINA1. Statistical analysis was performed by nonparametric Mann–Whitney U test with SPSS Statistics 26.0 (IBM Corporation).

Transcriptomic analysis of SERPINA1-silenced HTR8/SVneo cells
Cells were disrupted with a 20-G needle and 1-ml syringe. RNA isolation was done with the RNeasy Micro Kit (Qiagen), and the quality of isolated RNA was checked with an Agilent 2100 Bioanalyzer system at the Biocenter Oulu Sequencing Center, Finland.

RNA sequencing was done at the Finnish Functional Genomics Centre (FFGC; Turku, Finland). Transcriptomes of SERPINA1-silenced cells (n = 3) and negative control cells (n = 3) were determined with the Illumina HiSeq high-throughput sequencing system. Sequencing data were analyzed by the Bioinformatics Unit Core Service at the Turku Centre for Biotechnology, Finland.

Verification of transcriptomic data from SERPINA1-silenced HTR8/SVneo cells by qRT-PCR
Results from the RNA sequencing data of SERPINA1 knockdown experiments were verified by qRT-PCR in the manner described above. ACTG1, CEACAM1, FNI, and SLIT2 were chosen from the RNA sequencing data from the SERPINA1 knockdown. Primers and probes were forward 5′-GCCAGGATCCCTAAGTCTCA-3′ and reverse 5′-GTAGAAGGAGTGGTCCAGA-3′ for ACTG1 (UPL probe #9), forward 5′-CCCATCATGCTGAACGTAAA-3′ and reverse 5′-AGGCCCACACTCCTACAC-3′ for CEACAM1 (UPL probe #57), forward 5′-GCCAGAGTCCCCCTACTACA-3′ and reverse 5′-GTCTTCAGAAGTGCTCTACTCA-3′ for FNI (UPL probe #52), and forward 5′-CTTCCAGAGCACACACAGAAA-3′ and reverse 5′-CGTCTAGAAGTCTCTACTCA-3′ for SLIT2 (UPL probe #79). Probes were from the UPL Set (Roche Diagnostics). Each qPCR measurement was done in triplicate. Levels were normalized against the CYC1 level, and relative quantifications were then assessed with the ΔΔ cycle threshold method as described previously.

Results
Placental proteomes of preterm birth
Levels of 24 proteins were either up- or downregulated in SPTB vs. STB placentas (Figs. 2 and 3, Table 1). In the basal plate of SPTB placentas, the upregulated proteins were actin cytoplasmic 1 (ACTB), annexin A5 (ANXA5), copine-1 (CPNE1), elongation factor 2 (EEF2), hemoglobin subunit γ-1/2 (HBG1/2), 78-kDa glucose-regulated protein (HSPA5), and serotransferrin (TF). Downregulated proteins in the basal plate of SPTB placentas were alpha-1 antitrypsin (AAT), serum albumin (ALB), serum amyloid P-component (APCS), apolipoprotein A-I (APOA1), clusterin (CLU), ferritin light chain (ab6328, 1:250 dilution, Abcam), mouse anti-human vitronectin antibody (MAB88917, 1:250 dilution, Merck), mouse anti-human collagen IV antibody (MA5-13437, 1:250 dilution, Thermo Fisher Scientific), mouse anti-human Rab7 antibody (sc-376362, 1:250, Santa Cruz), and mouse anti-human CD63 antibody (sc-365604, 1:250, Santa Cruz). Primary antibody incubations were done at room temperature for 1 h. Secondary antibodies were goat anti-rabbit IgG Alexa Fluor 488 conjugate (S4412, 1:500 dilution, Cell Signaling Technology) and goat anti-mouse IgG Alexa Fluor 594 conjugate (S8890, 1:500 dilution, Cell Signaling Technology). Tissue samples were observed with a Leica SP8 FALCON laser scanning confocal microscope, and images were acquired with LAS X software. Excitation wavelengths were 499 nm for Alexa Fluor 488 conjugate and 598 nm for Alexa Fluor 594 conjugate. Emission wavelengths were 509–593 nm for Alexa Fluor 488 conjugate and 608–782 nm for Alexa Fluor 594 conjugate. Objectives used were HC PL APO CS2 20×/0.75 DRY and HC PL APO CS2 63×/1.40 OIL. Primary antibodies were omitted in the negative controls.
In the chorionic plate of the placentas, CPNE1, EEF2, heterogeneous nuclear ribonucleoprotein K (HNRNPK), HSPA5, U8 snoRNA-decapping enzyme (NUDT16), and TF were upregulated in SPTB; downregulated proteins were AAT, APCS, CLU, fibrinogen β chain (FGB), fibrinogen γ (FGG), GSN, keratin type II cytoskeletal 8 (KRT8), keratin type I cytoskeletal 18 (KRT18), keratin type I cytoskeletal 19 (KRT19), TAGLN2, and VIM.

Ten proteins (AAT, APCS, CLU, CPNE1, EEF2, GSN, HSPA5, TF, TAGLN2, and VIM) out of the identified 24 proteins were up- or downregulated in both sides of the placenta (basal and chorionic plates) (Fig. 2). The rest were differentially regulated in either basal (ACTB, ALB, ANXA5, APOA1, FTL, HBG1/2, and ITIH4) or chorionic (FGB, FGG, HNRNPK, KRT8, KRT18, KRT19, and NUDT16) plates.

**Proteins associated with spontaneous birth in preterm placentas**

In SPTB and EPTB placental proteomes, 27 proteins either were up- or downregulated (Figs. 2 and 4, Table 2). In the basal plate of SPTB placentas, the upregulated proteins were ANXA5, chorionic somatomammotropin hormone 1/2 (CSH1/2), coagulation factor XIII A chain (F13A1), estradiol 17-β-dehydrogenase 1 (HSD17B1), HSPA5, endoplasmin (HSP90B1), plasminogen activator inhibitor 2 (SERPINB2), and tryptophan-tRNA ligase (WARS). Downregulated proteins in SPTB placental basal plates were AAT, α-2-HS-glycoprotein (AHSG), ALB, annexin A4 (ANXA4), brain acid soluble protein 1 (BASP1), coflin-1 (CFL1), (FTL), gelsolin (GSN), inter-α trypsin inhibitor heavy chain H4 (ITIH4), transgelin-2 (TAGLN2), and vimentin (VIM).
chloride intracellular channel protein 4 (CLIC4), EF-hand domain-containing protein D1 (EFHD1), ERO1-like protein α (ERO1L), ezrin (EZR), glutathione S-transferase ω-1 (GSTO1), KRT19, lumican (LUM), peroxiredoxin-4 (PRDX4), peroxiredoxin-6 (PRDX6), protein S100-A6 (S100A6), and vimentin (VIM).

In the chorionic plate of SPTB placentas, CSH1/2, F13A1, and haptoglobin (HP) were upregulated; downregulated proteins were ANXA4, BASP1, CLIC3, EFHD1, ERO1L, EZR, and PRDX6. Eight proteins (ANXA4, BASP1, CSH1/2, EFHD1, ERO1L, EZR, F13A1, and PRDX6) out of the identified 27 proteins were up- or downregulated in both the basal and chorionic plates (Fig. 2). The rest were regulated in either the basal (AAT, AHSG, ALB, ANXA5, CFL1, CLIC4, GSTO1, HSD17B1, HSPA5, HSP90B1, KRT19, LUM, PRDX4, SERPINB2, S100A6, VIM, and WARS) or the chorionic (CLIC3 and HP) plate of the placenta.

Variations in protein expression levels in basal and chorionic plates of SPTB placentas

Comparisons of the two opposing sites of the placenta, the basal and chorionic plates, revealed different protein expression profiles (Additional file: Fig S3, Table 3). There were higher levels of EEF2, HNRNPK, and WARS expression in the basal plate compared to the chorionic plate of SPTB placentas. By contrast, expression levels of AAT, ALB, annexin A3 (ANXA3), APCS, APOA1, complement factor B (CFB), cofillin-1 (CFL1), CLU, GSN, ITIH4, KRT19, lumican (LUM), protein S100-A6 (S100A6), tropomyosin α-1 chain (TPM1), and tropomyosin β chain (TPM2) were lower in the basal plate than in the chorionic plate in SPTB placentas. These findings indicate that there are local variations in protein levels in the placenta. The local variations in AAT, ALB, APOA1, CFB, CFL1, ITIH4, KRT19, and S100A6 levels were observed exclusively in SPTB placentas.
### Table 1 Differences between spontaneous preterm and spontaneous term birth in the human placental proteome

| Spot | Protein | UniProt-KB | Description | Theoretical pl/ MW (kDa) | Detected pl/ MW (kDa) | Ratio | T vs P | Ch | Ba |
|------|---------|------------|-------------|--------------------------|-----------------------|-------|-------|-----|-----|
| 26   | AAT     | P01009     | α-1-antitrypsin (isoform 1) | 5.37 (5.37-44) 4.92 60 | (-1.28) -1.50 |
| 27   | AAT     | P01009     | α-1-antitrypsin (isoform 1) | 4.97 59 | -1.45 -1.63 |
| 38   | AAT     | P01009     | α-1-antitrypsin (isoform 1,2) | 4.82 51 | -2.39 (-2.01) |
| 39   | AAT     | P01009     | α-1-antitrypsin (isoform 1,2) | 4.86 51 | -2.16 (-1.82) |
| 85*  | ACTB    | P01009     | Actin, cytoplasmic 1 (fragment) | 5.29 (5.29-42) 4.93 18 | (1.33) 2.48 |
| 18   | ALB     | P02768     | Serum albumin | 5.92 69 | 5.71 66 (-1.05) -1.52 |
| 84*  | ANXAS   | P08756     | Annexin A5 (fragment) | 4.93 36 (4.93 36) 4.83 18 | (1.35) 2.19 |
| 67   | APC      | P10909     | Clusterin (isoform 3) | 6.19 32 4.76 36 | (-1.44) -1.52 |
| 73   | APOA1   | P02647     | Apolipoprotein A-I | 5.61 59 | 5.09 23 (-1.44) -1.52 |
| 58   | CLU     | P10909     | Clusterin (isoform 3) | 6.19 32 | 4.76 36 (-3.08) -1.96 |
| 59   | CLU     | P10909     | Clusterin (isoform 3) | 4.82 35 | -2.98 (-1.75) |
| 60   | CLU     | P10909     | Clusterin (isoform 3) | 4.88 34 | 2.99 (-1.49) |
| 23   | CPNE1   | Q99829     | Copine-1 | 5.52 59 | 5.56 63 1.62 1.95 |
| 9    | EEF2    | P13439     | Elongation factor 2 | 6.41 95 (6.42 95) 6.42 95 | 2.60 1.94 |
| 48*  | FGB     | P02675     | Fibrinogen β chain (C-terminal fragment) | 8.54 56 (7.95 51) 5.51 38 | (-3.04) -1.39 |
| 49*  | FGB     | P02675     | Fibrinogen β chain (C-terminal fragment) | 5.71 39 | 2.84 (-1.44) |
| 50*  | FGB     | P02675     | Fibrinogen β chain (C-terminal fragment) | 5.85 38 | 2.46 (-1.35) |
| 11   | FGG     | P02679     | Fibrinogen γ (isoform γ-B,A) | 5.37 52 (5.24 48) 5.41 95 | -3.59 (-1.99) |
| 12   | FGG     | P02679     | Fibrinogen γ (isoform γ-B,A) | 5.47 94 | 3.42 (-1.83) |
| 13   | FGG     | P02679     | Fibrinogen γ (isoform γ-B,A) | 5.54 94 | -2.91 (-1.68) |
| 14   | FGG     | P02679     | Fibrinogen γ (isoform γ-B,A) | 5.58 94 | 2.67 (-1.57) |
| 78   | FTL     | P01292     | Fibrin light chain | 5.50 20 (5.50 20) 5.50 20 | (1.29) -2.73 |
| 8    | GSN     | P06396     | Gelsolin (isoform 1) | 5.90 86 (5.72 83) 5.82 95 | -1.94 -1.79 |
| 89   | HBG1/2  | P69891/2   | Hemoglobin subunit gamma-1/2 | 6.64 16 (6.71 16) 6.36 12 | (1.38) 2.55 |
| 28   | HNRNPK  | P69891/2   | Heterogeneous nuclear ribonucleoprotein K (isoform 1-3) | 5.39 51 | 5.39 57 | 2.06 (1.33) |
| 17   | HSPA5   | P10909     | 78 kDa glucose-regulated protein | 5.07 72 (5.01 70) 5.01 71 | 2.60 2.73 |
| 1    | ITH4    | Q14624     | Inter-alpha-trypsin inhibitor heavy chain H4 (isoform 1) | 6.51 103 (6.11 100) 4.90 137 (-1.08) | -1.53 |
| 2    | ITH4    | Q14624     | Inter-alpha-trypsin inhibitor heavy chain H4 (isoform 1) | 4.92 136 | (-1.00) -1.58 |
| 3    | ITH4    | Q14624     | Inter-alpha-trypsin inhibitor heavy chain H4 (isoform 1) | 4.94 135 | (-1.05) -1.63 |
| 4    | ITH4    | Q14624     | Inter-alpha-trypsin inhibitor heavy chain H4 (isoform 1) | 4.96 135 | (-1.18) -1.56 |
| 30   | KRT8    | P05787     | Keratin, type II cytoskeletal 8 (isoform 1,2) | 5.52 54 | 5.24 47 | -1.55 (-1.34) |
| 31   | KRT8    | P05787     | Keratin, type II cytoskeletal 8 (isoform 1,2) | 5.33 50 | -2.48 (-1.54) |
| 54*  | KRT8    | P05787     | Keratin, type II cytoskeletal 8 (isoform 1,2, fragment) | 4.85 38 | -5.02 (-3.82) |
| 57*  | KRT8    | P05787     | Keratin, type II cytoskeletal 8 (isoform 1,2, fragment) | 4.79 37 | -4.70 (-3.49) |
| 5    | KRT8    | P05787     | Keratin, type II cytoskeletal 18 | 5.34 48 (5.34 48) 5.29 102 | -2.03 (-1.83) |
| 6    | KRT18   | P05787     | Keratin, type II cytoskeletal 18 | 5.35 102 | -2.19 (-2.07) |
| 56*  | KRT19   | P05787     | Keratin, type II cytoskeletal 19 (C-terminal fragment) | 5.05 44 | 4.74 37 | -2.28 (-1.98) |
| 79   | NUJ016  | Q96DE0     | U8 snoRNA-decapping enzyme (isoform 1) | 6.38 21 | 6.33 21 | 2.54 (4.78) |
| 10   | TF      | P02787     | Serotonin reuptake transporter | 6.81 77 (6.70 75) 6.02 90 | 2.43 1.95 |
| 80   | TAGLN2  | P37802     | Transgelin-2 (isoform 1,2) | 8.41 22 (8.45 22) 5.59 19 | -1.91 -1.75 |
| 41   | VIM     | P06767     | Vimentin | 5.05 54 (5.05 54) 4.71 44 | -1.77 -1.69 |
| 24   | –       | –          | – | 5.53 56 | 2.01 2.04 |

Spot numbers are according to Additional file: Fig S1. Descriptions and UniProt accession numbers for the identified spots are shown. Spots belonging to the same protein are clustered. Protein fragments are indicated with asterisks. Specific protein isoforms were validated according to spot positions in the gel and the covered protein sequence, as well as isoform-specific peptides obtained by mass spectrometry. Theoretical spot identifications were calculated according to full or mature (in parentheses) protein sequences, whereas detected spot positions in the gel were determined according to selected marker spots. If the identified spot allowed for the presence of several isoforms, theoretical values were indicated for the most common isoform. Ratio shows the change in mean normalized spot volumes between spontaneous preterm (P) and term (T) birth or between basal (Ba) and chorionic (Ch) plates of the placenta. Changes with no significance (p > 0.05) are denoted by parentheses. Spot 24 was not identified. For more details about protein levels, statistical significance, and protein identification, see Additional file: Tables S1 and S3. Isoelectric point (pI)
AAT/SERPINA1 associated with preterm birth in proteome and whole exome sequencing data comparisons

We identified six proteins for which levels were associated with SPTB (SPTB vs. STB proteomics with SPTB vs. EPTB proteomics) (Fig. 2): AAT, ALB, ANXA5, HSPA5, KRT19, and VIM. To obtain further evidence of a role for these proteins in spontaneous preterm labor, we searched for rare (minor allele frequency [MAF] < 1%) and common (MAF < 10%) potentially damaging variants (categories 1–3) in ALB, ANXA5, HSPA5, KRT19, SERPINA1, and VIM in whole exome sequencing (WES) data. The WES data included maternal exomes from Northern Finnish and Danish population sets and from the fetal exomes of the Northern Finnish population set. Of ALB, ANXA5, HSPA5, KRT19, SERPINA1, and VIM, only the exonic variants of HSPA5 and SERPINA1 were found in at least two different families (Table 4). In total, there were three variants of SERPINA1 in four different families and one variant of HSPA5 in two families. All of these variants were predicted to be damaging by the SIFT and PolyPhen-2 tools (Table 4). As the role of HSPs in SPTB was studied previously [35], we focused on AAT/SERPINA1.

Rare, potentially damaging SERPINA1 variants in families with recurrent preterm birth

Two out of three SERPINA1 variants from the WES data were considered likely to affect the function of AAT (Fig. 5). Variant rs28929474 (E366K, also known as Z variant) changes a glutamate into lysine, which results in unstable AAT and retention in the endoplasmic reticulum with a reduction in serum levels [41–43]. Variant rs28929470 (R247C, also known as F variant) has no effect on AAT serum levels but does result in a reduced association with the target protease [44, 45] because of loss of an important electrostatic interaction when arginine is substituted for cysteine (Fig. 5). Thus, the SERPINA1 variants identified by WES affect the functionality of AAT. Moreover, SERPINA1 has approximately 200 significant expression quantitative trait loci (eQTLs) in GTEx v8 data (e.g., in whole blood, cultured fibroblasts, and across tissues) that may contribute to the lower expression levels of SERPINA1 observed in the SPTB cases included in the proteomics data. These findings suggest that either low expression levels of SERPINA1 or dysfunctional AAT may be predisposing factors for premature birth.
Table 2 Differences between spontaneous and elective preterm birth in the human placental proteome

| Spot | Protein | UniProt-KB | Description | Theoretical pI/ MW (kDa) | Detected pI/ MW (kDa) | Ratio | E vs S |
|------|---------|------------|-------------|--------------------------|----------------------|-------|-------|
|      |         |            |             |                          |                      |       | Ch    | Ba    |
| 26   | AAT     | P01009     | α-1-antitrypsin (isoform 1 or 2) | 5.37/ 46.71 (5.37/ 44.34) | 4.93 60 (-1.09) -1.53 |
| 32   | AHSG    | P02765     | α-2-HS-glycoprotein (inactive protein with propeptide) | 5.43/ 39.3 (5.43/ 30.20) | 4.56 57 (-1.15) -1.77 |
| 18   | ALB     | P02768     | Serum albumin (isoform 1) | 5.92 69 (5.67/ 66.5) | 5.71 66 (1.21) -1.52 |
| 19   | ALB     | P02768     | Serum albumin (isoform 1) | 5.76 66 (1.15) -1.51 |
| 20   | ALB     | P02768     | Serum albumin (isoform 1) | 5.82 66 (1.14) -1.57 |
| 64   | ANXA4   | P09525     | Annexin A4 (isoform 1) | 5.83/ 35.9 (5.84/ 35.8) | 5.66 30 (-2.03) -1.97 |
| 83   | ANXA5   | P08758     | Annexin A5 | 4.93/ 35.9 (4.93/ 35.8) | 4.90 18 (1.58) 2.08 |
| 40   | BSP1    | P80723     | Brain acid soluble protein 1 (isoform 1) | 4.62/ 22.7 (4.62/ 22.6) | 4.54 50 (-2.42) -3.23 |
| 81   | CFI      | P23528     | Cofilin-1 | 8.22/ 18.5 (8.26/ 18.4) | 6.01 19 (-1.15) -2.43 |
| 71   | CLIC3   | O95833     | Chloride intracellular channel protein 3 | 5.99/ 26.6 | 5.89 26 (-1.75) (-1.69) |
| 66   | CLIC4   | Q9Y696     | Chloride intracellular channel protein 4 | 5.45/ 28.8 (5.45/ 28.6) | 5.39 26 (1.05) -1.56 |
| 76   | CSH1/2  | P0DML2/3   | Chorionic somatomammotropin hormone 1/2 (isoform 1) | 5.35/ 25.0 (5.33/ 22.3) | 5.43 22 (3.22) 3.14 |
| 77   | CSH1/2  | P0DML2/3   | Chorionic somatomammotropin hormone 1/2 (isoform 1) | 5.59 22 (2.17) 2.08 |
| 86   | CSH1/2  | P0DML2/3   | Chorionic somatomammotropin hormone 1/2 (isoform 1, fragment) | 5.67 15 (2.07) 3.09 |
| 65   | EFHD1   | Q9U8P0     | EF-hand domain-containing protein D1 (isoform 1) | 5.34/ 26.9 | 5.22 28 (-2.01) -2.48 |
| 22   | ERO1L   | Q9HE7      | ERO1-like protein α | 5.48/ 54.4 (5.37/ 51.9) | 5.53 63 (-1.66) -2.78 |
| 16   | EZR     | P15311     | Ezrin | 5.94/ 69.4 (5.95/ 69.3) | 5.88 82 (-2.01) -2.69 |
| 15   | F13A1   | P00488     | Coagulation factor XII A chain (inactive protein with propeptide) | 5.75/ 83.5 (5.71/ 79.2) | 5.74 88 (2.09) 1.98 |
| 70   | GSTO1   | P78417     | Glutathione S-transferase u-1 (isoform 1) | 6.24/ 27.6 (6.23/ 27.4) | 5.69 27 (-1.65) -2.02 |
| 42   | HP      | P00738     | Haptoglobin (isoform 1 or 2) | 4.79 44 (1.47) |
| 52   | HSD1B1  | P14061     | Estradiol 17-β-dehydrogenase 1 | 5.46/ 34.9 (5.47/ 34.8) | 5.46 35 (1.35) 1.64 |
| 53   | HSD1B1  | P14061     | Estradiol 17-β-dehydrogenase 1 | 5.59 35 (1.43) 1.70 |
| 17   | HSPA5   | P11021     | 78 kDa glucose-regulated protein | 5.07/ 73.2 (5.01/ 70.5) | 5.01 71 (1.99) 2.78 |
| 21   | HSP0081 | P14625     | Endoplasmic reticulum chaperone | 4.76/ 92.5 (4.73/ 90.2) | 5.09 97 (1.88) 1.85 |
| 43   | KRT19   | P08727     | Keratin, type I cytoskeletal 19 | 5.05/ 44.2 | 4.85 41 (-1.11) -1.74 |
| 44   | KRT19   | P08727     | Keratin, type I cytoskeletal 19 | 4.87 41 (-1.18) -1.76 |
| 45   | KRT19   | P08727     | Keratin, type I cytoskeletal 19 | 4.90 41 (-1.22) -1.59 |
| 46   | KRT19   | P08727     | Keratin, type I cytoskeletal 19 | 4.93 41 (-1.22) -1.64 |
| 56*  | KRT19   | P08727     | Keratin, type I cytoskeletal 19 (C-terminal fragment) | 4.74 37 (-1.04) -1.70 |
| 34   | LUM     | P51884     | Lumican | 6.16/ 38.4 (6.17/ 36.7) | 4.51 53 (1.44) -1.81 |
| 68   | PRDX4   | Q13162     | Peroxiredoxin-4 | 5.86/ 30.5 (5.54/ 26.6) | 5.61 25 (-1.22) -1.55 |
| 75   | PRDX6   | P30041     | Peroxiredoxin-6 | 6.00/ 25.0 (6.02/ 24.9) | 5.82 25 (-1.66) -1.69 |
| 47   | SERPIN82| P05120     | Plasminogen inhibitor 2 | 5.46/ 46.6 | 5.51 42 (1.55) 1.96 |
| 88   | S100A6  | P06703     | Protein S100-A6 | 5.32/ 10.2 | 4.95 10 (-1.17) -2.19 |
| 41   | VIM     | P08670     | Vimentin | 5.05/ 53.7 (5.05/ 53.5) | 4.71 44 (1.05) -1.54 |
| 29   | WARS    | P23381     | Tryptophan-6Rna ligase (isoform 1 or 2) | 5.83/ 53.2 (5.83/ 53.0) | 5.83 55 (-1.02) 1.65 |
| 24   | –       | –          | –           | –                        | 5.52 56 (1.39) 2.39 |
| 69   | –       | –          | –           | –                        | 5.94 29 (2.39) 2.51 |
| 72   | –       | –          | –           | –                        | 5.15 25 (1.79) 2.52 |
| 82   | –       | –          | –           | –                        | 4.94 19 (2.49) 2.39 |

Spot numbers are according to Additional file: Fig S1. Descriptions and UniProt accession numbers for the identified spots are shown. Spots belonging to the same protein are clustered. Protein fragments are indicated with asterisks. Specific protein isoforms were validated according to spot positions in the gel and the covered protein sequence, as well as isoform-specific peptides obtained by mass spectrometry. Theoretical spot identifications were calculated according to full or mature (in parentheses) protein sequences, whereas detected spot positions in the gel were determined according to selected marker spots. If the identified spot allowed for the presence of several isoforms, theoretical values were indicated for the most common isoform. Ratio shows the change in mean normalized spot volumes between spontaneous (S) and elective (E) preterm birth in basal (Ba) and chorionic (Ch) plates of the placenta. Changes with no significance (p > 0.05) are denoted by parentheses. Spots 24, 69, 72, and 82 were not identified. For more details about protein levels, statistical significance, and protein identification, see Additional file: Tables S2 and S3. Isoelectric point (pI)
To investigate the role of AAT in the placenta, we carried out a western blot analysis of AAT expression in samples taken from different sites of the placenta (SPTB $n = 6$ placentas, STB $n = 6$ placentas) (Additional file: Fig S2). As
Table 4  Variants of *HSPA5* and *SERPINA1* identified by whole exome sequencing

| Gene symbol | Country | Family ID | Status   | Chr<sup>a</sup> | Reference allele | Sample allele | rsID       | Protein variant | MAF<sup>b</sup> European Finnish | MAF<sup>b</sup> European non-Finnish | SIFT Function Prediction | PolyPhen-2 Function Prediction |
|-------------|---------|-----------|----------|----------------|-----------------|---------------|------------|----------------|--------------------------------|---------------------------------|--------------------------|---------------------------|
| *HSPA5*     | Finland | 24        | Mother   | 9              | T               | C             | rs56136100  | E557G          | 0.01341                        | 0.00213                         | Damaging                 | Benign                    |
| *HSPA5*     | Denmark | 60        | Mother   | 9              | T               | C             | rs56136100  | E557G          | 0.01341                        | 0.00213                         | Damaging                 | Benign                    |
| *SERPINA1*  | Finland | 159       | Mother   | 14             | C               | T             | rs28929474  | E366K          | 0.01796                        | 0.01835                         | Damaging                 | Probably damaging           |
| *SERPINA1*  | Finland | 159       | Child    | 14             | C               | T             | rs28929474  | E366K          | 0.01796                        | 0.01835                         | Damaging                 | Probably damaging           |
| *SERPINA1*  | Finland | 159       | Child    | 14             | C               | T             | rs28929474  | E366K          | 0.01796                        | 0.01835                         | Damaging                 | Probably damaging           |
| *SERPINA1*  | Finland | 210       | Child    | 14             | C               | T             | rs28929474  | E366K          | 0.01796                        | 0.01835                         | Damaging                 | Probably damaging           |
| *SERPINA1*  | Finland | 185       | Mother   | 14             | C               | T             | rs121912712 | E387K          | 0.00278                        | 0.00007                         | Damaging                 | Benign                    |
| *SERPINA1*  | Denmark | 25        | Mother   | 14             | G               | A             | rs28929470  | R247C          | 0.00056                        | 0.00418                         | Damaging                 | Possibly damaging           |

<sup>a</sup> Chromosome  
<sup>b</sup> Minor allele frequency
in placental proteomics, western blot analysis revealed that AAT was downregulated in SPTB compared to STB placentas, particularly in the chorionic plate ($p = 0.006$). In SPTB vs. STB proteomics, AAT1 expression levels were significantly different: 1.6-fold ($p = 0.002$) and 2.4-fold ($p = 0.01$) in the basal and chorionic plates, respectively.

Next, we studied whether AAT is regulated at the transcriptional level by analyzing mRNA expression of SERPINA1 in placental samples from SPTB ($n = 18$) and STB ($n = 20$) by qRT-PCR. SERPINA1 mRNA expression was lower in SPTB compared to STB placentas ($p = 0.001$, fold change [FC] = $-1.91$; Fig. 6). qRT-PCR of SERPINA1 indicated that low levels of both AAT/SERPINA1 protein and mRNA were associated with SPTB.

### AAT colocalizes with fibrinoid deposit components in placenta

We used immunohistochemistry to assess the localization of AAT in placental tissues. Samples of the basal plate from SPTB and STB deliveries were stained with anti-human AAT antibody (Fig. 7). Staining was strong for AAT in cytotrophoblasts and syncytiotrophoblasts in the basal plate. We also observed AAT in the extracellular matrix of the decidua and AAT-stained granules in the cytosol of cyto- and syncytiotrophoblasts (Figs. 7 and 8A).

Next, we used immunoelectron microscopy (immuno-EM) to visualize more precisely the intracellular localization of AAT in placental trophoblasts and in the decidua. The AAT granules seen in cyto- and syncytiotrophoblasts (Fig. 8A) originated from densely packed AAT inside vesicles (Fig. 8B). The dense bodies, vesicles, and...
surface microvilli suggest that these syncytiotrophoblasts are involved in endocrine activity [47, 48]. In the extracellular matrix, we observed AAT in fibrillar networks (Additional file: Fig S4A and C) and in dense structures (Additional file: Fig S4B) that may be decidual fibrinoid deposits. These observations suggest that the protease inhibitor activity of AAT may play a role in regulating the amount and composition of fibrinoid deposits in the human placenta.

To further characterize the AAT-containing granules, we did fluorescence colocalization analysis with AAT- and exosome/endosome-specific antibodies. We used Rab7 and CD63 as endosome and exosome markers, respectively. Rab7 is known particularly as a late endosome and lysosome marker. As seen in Additional file: Fig S5, AAT and Rab7 did not colocalize. Thus, the granules containing AAT were not late endosomes or lysosomes. By contrast, AAT and CD63 colocalized in the same areas in the villi, which suggests that the granules were exosomes. However, 3D analysis of the images suggested that AAT and CD63 were not within the same granules (Additional file: Fig S5). These results did not allow us to determine the type of granules in which AAT was located.

Decidual fibrinoid deposit, also known as matrix-type fibrinoid, is secreted by decidual trophoblasts and consists of collagen, laminin, vitronectin, and fibronectin including fetal fibronectin [49]. In addition to anti-AAT staining, we performed immuno-EM staining with an anti-human fibronectin antibody that does not recognize plasma fibronectin. Immuno-EM staining revealed that fibronectin was mostly found in fibrillar networks (Additional file: Fig S4A and C), which suggests that these placental regions are fibrinoid deposits. These results also indicate that AAT is found in decidual fibrinoid deposits.

Next, we further characterized the fibrinoid structures in which AAT was localized by fluorescence colocalization analysis. There are two main subtypes of fibrinoids, fibrin type and matrix type, which differ in structure, composition, and function [50]. Fibrin-type fibrinoid is the result of blood clotting and is mostly composed of fibrin, albumin, immunoglobulins, and different types of fibronectins. Matrix-type fibrinoid is a secretory product of decidual trophoblast cells and is composed of collagen type IV, laminin, heparan sulfate, vitronectin, and fibronectins [49, 50]. EM analysis revealed that AAT may be associated with matrix-type fibrinoids.

There are three types of compartments in matrix-type fibrinoid [49]. Subtype 1 is densely granular and basal lamina-like and composed of collagen IV and laminin [49, 50]. To determine if AAT is located in matrix-type fibrinoid subtype 1 deposits, we stained tissue with both AAT- and collagen IV-specific antibodies. As seen in Fig. 9, localization of AAT and collagen IV was similar and mostly around decidual trophoblasts, whereas there was only a modest overlay with the subtype 2 marker.

---

**Fig. 6** Placental mRNA expression of *SERPINA1* in spontaneous preterm birth and spontaneous term birth. Relative mRNA expression of *SERPINA1* in basal plate of the placenta. mRNA levels were normalized against the housekeeping gene *CYC1*. Statistical analysis was performed with Mann–Whitney *U* test to discover differences. Quartiles represented by box and whiskers. Ends of whiskers represent minimum and maximum values. Inside the box, median is indicated with a line and mean value is represented with a square.
vitronectin and the subtype 3 marker fibronectin. Thus, fluorescence colocalization analysis revealed that AAT colocalizes predominantly with subtype 1 fibrinoid deposits in placenta.

**siRNA-induced knockdown of SERPINA1 indicates that SERPINA1 regulates actin cytoskeleton pathway and extracellular matrix organization**

To investigate potential functions of SERPINA1 in placental cells, we silenced SERPINA1 expression in the HTR-8/SVneo human trophoblast cell line with small interfering RNAs (siRNAs). Based on qRT-PCR, silencing efficacy was 94% (Additional file: Fig S6). Next, we characterized the transcriptomes of HTR-8/SVneo cells in which SERPINA1 was silenced, as well as of cells treated with siRNA Universal Negative Control #1. The threshold we used for the analysis was a false discovery rate (FDR)–adjusted p value of ≤0.05 and an FC of ≥1.5. Transcriptomic data analysis identified 442 upregulated and 623 downregulated genes after SERPINA1 knockdown compared to samples treated with siRNA Universal Negative Control. Up- and downregulated genes that had fold changes of >2.0 are in Additional file: Tables S4 and S5.

KEGG pathway database analyses (Additional file: Table S6) identified regulation of actin cytoskeleton as the most affected pathway after SERPINA1 knockdown (p = 0.00013). Altogether, 26 genes related to regulation of actin cytoskeleton were affected by SERPINA1 knockdown. Among the affected genes was fibronectin 1 (FN1).

**Fig. 7** Placental localization of AAT in spontaneous preterm (SPTB) and term (STB) births. Samples from SPTB and STB placentas were immunostained with anti-human AAT antibody. Samples were from the basal plate (maternal side) and from the decidua of the placenta. Immunostaining is indicated by arrowheads in villous trophoblasts (cytotrophoblasts and syncytiotrophoblasts) and arrows in decidual trophoblasts. Original magnification × 20 in all figures. Control is isotype control for immunostaining. Scale bar: 100 μm
fFN is one of the best predictors of preterm birth in all populations studied to date [51].

A Gene Ontology (GO) Biological Processes search (Additional file: Table S7) identified positive regulation of cell migration (27 genes) and extracellular matrix organization (27 genes) as processes that are affected by SERPINA1 silencing. A GO Cellular Component (GO-CC) search showed that SERPINA1 knockdown particularly affected genes that encode proteins found in the proteinaceous extracellular matrix (32 genes) and extracellular exosomes (186 genes) (Additional file: Table S8).

The gene most strongly regulated by SERPINA1 knockdown was actin gamma 2, smooth muscle (ACTG2). ACTG2 is involved in processes such as Slit–Robo signaling in development and actin nucleation by the ARP–WASP complex. A paralog of ACTG2, actin alpha cardiac muscle 1 (ACTC1), was also among the upregulated genes (p = 0.0001, FC = 3.43). Like ACTG2, ACTC1 is involved in Slit–Robo signaling in development. Moreover, SLIT2 (p = 0.0009, FC = 2.08) and SLIT3 (p = 0.0006, FC = 2.28) were among the upregulated genes after SERPINA1 silencing. We previously showed that Slit–Robo signaling has a role in SPTB (Tiensuu et al. 2019); thus, we investigated possible interactions further.

qPCR showed that SLIT2 is upregulated (p = 0.004) [39] and SERPINA1 downregulated (Additional file: Fig S7) in SPTB placentas. Based on these findings, we asked whether mRNA levels of SERPINA1 and SLIT2 correlated in the placenta. When we compared qPCR results using exactly the same placenta specimens, we found that SERPINA1 and SLIT2 levels were significantly correlated (p = 0.006). These data indicate that SERPINA1 may be an important regulator of SLIT2 and, thus, Slit–Robo signaling.

To verify our findings from the RNA sequencing data, we used qRT-PCR to analyze the effect of SERPINA1 knockdown on expression levels of selected genes from a larger number of specimens (n = 6). We verified the results for ACTG2, one of the downregulated genes (carcinoembryonic antigen-related cell adhesion molecule 1 [CEACAM1]), one gene from the regulation of actin cytoskeleton pathway (FN1), and SLIT2. According to the sequencing data, FN1 and SLIT2 were both upregulated after SERPINA1 knockdown.

The qRT-PCR results were in line with those from transcriptome sequencing (Additional file: Table S9). Knockdown of SERPINA1 downregulated mRNA expression of CEACAM1 (Additional file: Fig S7) and upregulated ACTG2, FN1, and SLIT2 mRNA expression (Additional file: Fig S7), similar to the results

![Fig. 8](image-url) Stained cytoplasmic AAT granules in syncytiotrophoblasts of spontaneous term birth placenta. In both A and B, samples from the basal plate (maternal side) of the placenta immunostained with anti-human AAT antibody. A Immunohistochemistry image of AAT staining in syncytiotrophoblasts. Scale bar: 20 μm. B Immunoelectron microscopy image of AAT staining in syncytiotrophoblasts. Scale bar: 0.5 μm
of RNA sequencing. Thus, the RNA sequencing and qRT-PCR results are in accordance and confirm that SERPINA1 knockdown affects the expression genes associated with Slit–Robo signaling and regulation of the actin cytoskeleton in a cell culture model.

**Discussion**

Evaluation of the risk of giving birth preterm in human pregnancy is challenging due to a lack of accurate biomarkers and an incomplete knowledge of the mechanisms involved in the onset of SPTB [6]. According to epidemiological evidence, both maternal and fetal genomes are involved in regulation of the length of pregnancy [52]. The placenta and fetal membranes contain cells of both maternal and fetal origin that are in direct contact with each other [50], which requires immune tolerance to foreign antigens. Switch from anti-inflammatory state to proinflammatory state occurs in the normal delivery. Spontaneous preterm birth is regarded as a syndrome resulting from multiple causes, including infection or inflammation. Thus, it is likely that SPTB is the result of the changes in the infection or inflammation-related factors and pathways. The potential role of the placenta in regulation of the length of pregnancy was a focus of the present study.

Here, we analyzed the proteomes of the basal and chorionic plates of SPTB, STB, and EPTB placentas to identify proteins associated with both spontaneity and gestational age. We then identified proteins (ALB, ANXA5, HSPA5, KRT19, AAT, and VIM) associated with SPTB. The entire exons of these six proteins were then analyzed for potentially damaging variants in families with recurrent preterm births. Of the six candidates revealed by proteomics, SERPINA1 and HSPA5 had at least two potentially damaging variants. One HSPA5 variant was found in two families and two damaging SERPINA1 variants were found in three families. The SERPINA1 locus is

![Confocal microscopy images of human placenta expressing endogenous AAT, fibronectin, vitronectin, and collagen IV. Colocalization fluorescence image of AAT (green) and fibronectin (red) (top row), AAT (green) and vitronectin (red) (middle row), and AAT (green) and collagen IV (red) (bottom row). Middle columns are separate green channel, red channel, and brightfield images, which are shown merged in left column. Panels in right column show negative controls treated the same way as samples but with primary antibody omitted. Objective lens: HC PL APO CS2 ×20/0.75 DRY. Scale bar: 10 μm](image-url)
The RCL is the region of AAT that binds to the tar-
associated with disease. All three variants, however, are
variants of SERPINA1, rs121912712, changes glutamate
PINA1 SER-
of blood monocytes revealed that the degree of
AAT levels in maternal blood during pregnancy. A study
which tissues or cells contribute the most to elevated
in spontaneous abortions [21]. However, it is unknown
that produce AAT include macrophages and neutro-
AAT is produced by the liver and the lung. Types of cells
[47, 48].

The three WES variants that we identified in Fin-
land and Danish SPTB cases affect the function of AAT. Variant rs28929474 (Z variant) changes glutamate into
lysine (E366K) [55], while variant rs28929470 (F variant)
changes arginine into cysteine (R247C) [43, 55]. A third
variant of SERPINA1, rs121912712, changes glutamate
into lysine (E387K) and has not yet been reported to be
associated with disease. All three variants, however, are
located in a loop known as the reactive center loop (RCL)
[45]. The RCL is the region of AAT that binds to the tar-
gent protein, which results in the inhibition of proteases.
The Z variant has the most effect on the stability of AAT. This
variant resides in the endoplasmic reticulum [41–43]
and is eventually degraded, which results in reduced
anti-protease activity. The F variant does not influence
the amount of AAT; instead, it reduces the binding affin-
ity of AAT to proteases. With both Z and F variants, pro-
tease is not properly inhibited, which allows protease
activity to continue [56].

The unstable Z variant of AAT has been reported to
escape intracellular pathways of protein degradation
by forming AAT granules [43]. In immuno-EM images,
we observed AAT granules inside of cyto- and syncy-
tiotrophoblasts in both SPTB and STB placentas. This
suggests that similar granules are part of the common
secretory pathway of AAT. Based on our immunohistol-
ogy and immuno-EM analyses, we propose that AAT
is moving out of these cells into the intervillous space,
which consists of maternal blood. Moreover, in the anal-
ysis of SERPINA1 silencing affected genes, extracellu-
lar exosome was the most enriched GO term. These are
in line with the observation that AAT levels increase in
the blood of the mother during pregnancy [57]. Overall,
these dense bodies and vesicles are evident in syncytio-
trophoblasts and they are the site of metabolic activity
[47, 48].

In addition to its production by villous trophoblasts,
AAT is produced by the liver and the lung. Types of cells
that produce AAT include macrophages and neutro-
phins. AAT levels in maternal blood are exceptionally low
in spontaneous abortions [21]. However, it is unknown
which tissues or cells contribute the most to elevated AAT levels in maternal blood during pregnancy. A study
of blood monocytes revealed that the degree of SER-
PINAI1 promoter methylation decreases progressively
during pregnancy [58]. Furthermore, AAT serum lev-
els are several-fold higher in the end of pregnancy than
during the first trimester [57]. Our placental proteomic
findings show that low AAT content in the placenta is
associated with SPTB. According to our findings, SER-
PINAI1 mRNA levels are associated with those of AAT
protein levels in the placenta, regardless of the duration
of pregnancy or labor. This suggests that AAT is regu-
lated at the mRNA level, which leads to decreased levels
of the protein in SPTB. The lower AAT/SERPINA1 lev-
els in SPTB may be due to exonic variants or eQTL SNPs
that affect expression. Additionally, certain microRNAs
could regulate SERPINA1 mRNA levels.

To understand more about the function of AAT in
trophoblast cells, we silenced its expression in a continu-
ous human cell line of extravillous invading trophoblasts
(HTR8/SVneo). Altogether, 1065 genes were affected
at least 1.5-fold by SERPINA1 siRNA knockdown. Our
silencing experiment indicates that SERPINA1 regulates
many genes of the Slit–Robo signaling pathway. We pre-
viously showed that Slit–Robo signaling has a potential
role in SPTB [39]; in this genome-wide study, a SLIT2
variant was associated with SPTB, and in trophoblasts,
Slit–Robo signaling affected the expression of immune
response–modifying genes like inflammatory cytokines
and chemokines, which have proposed roles in the
onset and progression of spontaneous preterm labor
(5). Additionally, AAT was previously shown to induce
anti-inflammatory cytokines [21, 58, 59]. By contrast,
our SERPINA1 silencing experiment did not indicate
that cytokines were extensively affected by SERPINA1
silencing. However, AAT/SERPINA1 may regulate genes
related to infection, inflammation, and immune response
through regulation of the Slit–Robo signaling pathway.

Pathway analysis of genes affected by SERPINA1 silenc-
ing identified regulation of actin cytoskeleton as the
top pathway: 26 genes in this pathway were affected by
SERPINA1 silencing. Human placental syncytiotropho-
blast microvilli are supported by an underlying cytoskel-
eton that consists mainly of actin microfilaments [60].
The microvilli contain a core of actin filaments running
from the tip of the microvillus to the apical cytoplasm.
The surface of the syncytial trophoblast is covered by a
microvillous (brush) border that is in direct contact with
maternal blood. Thus, it is the site where a variety of
transport, enzymatic, and receptor activities take place.
Organization of the brush border membrane, as well as
other features of placental villus organization, could be
influenced by the distribution of cytoplasmic actin fila-
ments [61]. Therefore, by affecting the actin cytoskele-
on, AAT may influence placental villus organization and
its diverse functions.
A GO search identified the top GO terms affected by SERPINA1 knockdown as positive regulation of cell migration and extracellular matrix organization and revealed that SERPINA1 knockdown particularly affected genes that encode proteins secreted into extracellular spaces. Among these genes were collagen alpha-1 (IV) chain (COL1A1), laminin subunit alpha 2 (LAMA2), laminin subunit alpha-4 (LAMA4), and FNI. Proteins encoded by these genes are present in different types of fibrinoid deposits in the placenta [49]. This suggests that AAT has a role in extravillous fibrinoid matrix organization. The presence of AAT in the placenta was demonstrated previously in preeclampsia cases, in which AAT is particularly prominent in the fibrinoid region of the decidua and in villous trophoblasts [62]. In placentas from SPTB pregnancies, in addition to its presence in cyto- and syncytiotrophoblasts, we also observed AAT in the decidual fibrinoid matrix. In preeclampsia cases, increased AAT levels in the decidua are associated with more fibrinoid deposits in the same region [62]. Similarly, we propose that lower levels of AAT result in lower levels of fibrinoid deposits, as AAT levels were lower in biopsies from the basal plate of SPTB placentas compared to AAT levels in the basal plate of term or EPTB placentas. Lower anti-protease concentrations or activity may decrease resistance to protease-catalyzed degradation of fibrinoid deposits and release of fibrinoid deposit components, such as fFN. Elevated levels of fFN have indeed been measured in cervicovaginal fluids as an early index that predicts preterm delivery [10]. Moreover, our immuno-EM and immunofluorescence images indicate that AAT and fibronectin colocalize to some extent in the extravillous fibrinoid deposit region of the human placenta. However, AAT colocalized predominantly with another fibrinoid deposit component: collagen IV.

In previous studies, AAT is associated with fibrosis that takes place in response to tissue injury or inflammation and is defined by overproduction of extracellular matrix in the connective tissue [63]. For example, the SERPINA1 Z variant is associated with fibrotic liver disease [64]. By contrast, in pregnancy, fibrosis is linked to complications like preeclampsia [63]. Fibrosis in preeclamptic placentas is associated with stromal fibroblasts activated by the TGFβ signaling pathway, as treatment of placental fibroblasts with TGFβ1 leads to production of fibrosis-related factors like FN1 and COL4A1 [63]. Our silencing of SERPINA1 in trophoblast culture showed that SERPINA1 affects fibrosis-related factors like COL4A1 and FN1, which are also components of fibrinoid deposits in the placenta.

The amount of fibrinoid increases steadily throughout pregnancy. Fibrinoids have an immunosuppressive function that is mediated by binding to various types of antigens, which lowers the immunological load between mother and fetus [50, 65, 66]. Moreover, the fibrinoid barrier modulates trophoblast invasion into the uterus during early pregnancy [62, 67]. The presence of AAT in fibrinoid deposits suggests a mechanism for maintaining the stability and defense functions of fibrinoid. The lower placental expression levels of AAT in SPTB that we observed may promote inflammatory activation via the Slit–Robo pathway. Additionally, AAT is known to inhibit neutrophil elastase, which is required for normal resistance against infections, but which also can disrupt tissue homeostasis, especially in the lungs, if not adequately regulated [68, 69]. In the placenta, low anti-protease activity combined with proinflammatory activation may lead to proteolytic degradation of the fibrinoid structure, leakage of specific placental extracellular components into the cervix, and premature activation of labor.

AAT seems to influence multiple pathways in placenta (Fig. 10). We propose that fibrinoid deposits and their anti-inflammatory capacity are adversely affected by low concentrations or lack of function of AAT in the placenta. This may result in degradation of fibrinoid deposits and decreased resistance against proinflammatory mediators, with consequent promotion of early labor. In addition, the amount of fibrinoid affects trophoblast invasion [62, 67]. Our EM immunohistochemistry and fluorescence colocalization analyses showed an association between AAT and fibrinoid deposit. Displacement of fFN to the cervix may reflect ongoing degradation of fibrinoid tissue. We further speculate that AAT supplementation may delay the onset and progression of premature labor, similar to prophylactic treatment of emphysema associated with damaging SERPINA1 variants [70–72]. It has also been shown that AAT modulates TNF-α in neutrophils, such that low levels of AAT result in increased TNF-α signaling and neutrophil degranulation [73]. In the degranulation event, neutrophil elastase is released. Finally, disruption of maternal-fetal immune tolerance has been linked to chronic chorioamnionitis that often leads to spontaneous preterm labor and delivery [5]. It is interesting that experimental AAT therapy has induced immune tolerance during allograft transplantation [74]. Our hypothesis that AAT maintains fibrinoid deposits, moderates proinflammatory signaling from the placenta to the uterus, and delays premature labor/delivery remains to be proven.

**Conclusions**

The focus of the study was on the role of the placenta in regulation of the length of pregnancy. We analyzed proteomes of placentas to identify proteins associated with spontaneous preterm birth. Next, the entire exons of the identified proteins were analyzed for
potentially damaging variants in families with recurrent preterm births. These resulted in alpha-1 antitrypsin encoded by \textit{SERPINA1} in association with spontaneous preterm labor. Protein and mRNA levels of alpha-1 antitrypsin/\textit{SERPINA1} in the placenta were downregulated in spontaneous preterm births. Alpha-1 antitrypsin was expressed by villous trophoblasts in the placenta. Our immunoelectron microscopy and fluorescence colocalization analyses showed an association between alpha-1 antitrypsin and placental fibrinoid deposit with specific extracellular proteins. These fibrinoids have an immunosuppressive function that is mediated by binding to various types of antigens, which lowers the immunological load between mother and fetus. Alpha-1 antitrypsin is a protease inhibitor, and the presence of alpha-1 antitrypsin in fibrinoid deposits suggests a mechanism for maintaining the stability and defense functions of the fibrinoid. We propose that low alpha-1 antitrypsin levels result in low anti-protease activity combined with proinflammatory activation and lead to proteolytic degradation of the fibrinoid deposit structure, leakage of specific placental extracellular components into the cervix, and premature activation of labor. We further speculate that alpha-1 antitrypsin supplementation could delay the onset and progression of premature labor, similar to prophylactic treatment of emphysema associated with loss of function of alpha-1 antitrypsin in the lungs.

**Abbreviations**

AAT: Alpha-1 antitrypsin; ACTB: Actin cytoplasmic 1; ACTC1: Actin alpha cardiac muscle 1; ACTG2: Actin gamma 2, smooth muscle; AHSG: \(\alpha\)-2-HS-glycoprotein; ALB: Serum albumin; ANXA3: Annexin A3; ANXA4: Annexin A4; ANXA5: Annexin A5; AP5S: Amyloid P-component; APOA1: Apolipoprotein A-1; Ba: Basal plate; BAP1: Brain acid soluble protein 1; BSA: Bovine serum albumin; CD63: CD63 molecule; cDNA: Complementary DNA; CECA: Carcinoembryonic antigen-related cell adhesion molecule 1; CFL1: Cofilin-1; Ch: Chorionic plate; CLIC4: Chloride intracellular channel protein 4; CLU: Clusterin; COL4A1: Collagen alpha-1 (IV) chain; CPNE1: Copine-1; CFY1: Chorionic somatomamotropin hormone 1/2; CYC1: Cytochrome C1; EFHD1: EF-hand domain-containing protein 1; EM: Electron microscope; EPTB: Elective preterm birth; ERO1L: eRO1-like protein a; EZR: Ezrin; F13A1: Coagulation factor XIII A chain; FGGC: Finnish Functional Genomics Centre; FGF: Fibrinogen \(\beta\) chain; FGG: Fibrinogen \(\gamma\); FN1: Fibrinogen 1; FTI: Fibrinogen light chain; GA: Gestational age; GOBP: Gene ontology biological processes; GOCC: GO cellular component; GSN: Gelsolin; GSTO1: Glutathione S-transferase omega-1; HBGI: Hemoglobin subunit \(\gamma\)-1/2; HNRNPK: Heterogeneous nuclear ribonucleoprotein K; HP: Haptoglobin; HSD17B1: 17-\(\beta\)-hydroxysteroid dehydrogenase 1; HSP90: Endoplasmic; HSPA5: 78-KDa glucose-regulated protein; IgG: Immunoglobulin G; IL-6: Interleukin 6; IL-8: Interleukin 8; ITIH4: Inter-alpha trypsin inhibitor heavy chain H4; KRT18: Keratin type I cytoskeletal 18; KRT19: Keratin type I cytoskeletal 19; LAMA2: Laminin subunit alpha 2; LAMA4: Laminin subunit alpha 4; LUM: Lumican; MAF: Minor allele frequency; mRNA: Messenger RNA; NUDT16: U8 snRNA decapping enzyme; PBS: Phosphate buffered saline; PPROM: Preterm premature...
rupture of the membranes; PRDX4: Peroxiredoxin-4; PRDX6: Peroxiredoxin-6; PTB: Preterm birth; qRT-PCR: Real-time quantitative reverse transcription PCR; Rab7: Ras-related protein 7; S100A6: Protein S100-A6; SERPINA1: Serpin family A member 1; SERPINE2: Plasminogen activator inhibitor 2; sRNA: Small interfering RNA; SLIT2: Slit guidance ligand 2; SNP: Single-nucleotide polymorphism; SPTB: Spontaneous preterm birth; STB: Spontaneous term birth; TAGLN2: Transgelin-2; TF: Serotransferrin; TGFβ: Transforming growth factor beta; TNF-α: Tumor necrosis factor alpha; TPM1: Tropomyosin α-1 chain; TPM2: Tropomyosin β chain; VM: Vimentin; WARS: Tryptophan-tRNA ligase; WES: Whole exome sequencing.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02339-8.

Acknowledgements

We express our sincere thanks to all the families that participated in this study. We would like to thank Maant Haarala from University of Oulu for sample preparation and laboratory work. Sonja Eeli, Mia Lehto, and Pinta Viekiväinen from Oulu University Hospital are acknowledged for sample and data collection. The expertise of the Biocenter Oulu Electron Microscopy core facility, a member of Biocenter Finland, is gratefully acknowledged. We thank the Finnish Functional Genomics Center (supported by University of Turku, Åbo Akademi University, and Biocenter Finland) and the Medical Bioinformatics Centre of Turku Biocentre Centre for the sequencing data analysis. The Medical Bioinformatics Centre is supported by University of Turku, Åbo Akademi University, Biocenter Finland, and Elstar-Finland.

Authors’ contributions

HT, AMH, MJ, LJM, MH, and MR designed the research. HT, AMH, PT, AR, TM, JVH, SO, and UB performed the research. HT, AMH, PT, AR, TM, JNH, SO, and UB participated in data analysis. HT, AMH, PT, MH, and MR wrote the paper. All authors read and approved the final manuscript.

Funding

This study was supported by the grants from Jane and Aatos Erkko Foundation (NH, MR), Foundation for Pediatric Research (MR), the Sigurd Jusélius Foundation (NH), Competitive State Research Financing of the Expert Responsibility Area of Oulu University Hospital (MR), and Stiftelsen Alma och K. A. Snellman foundation (HT, AMH).

Availability of data and materials

Transcriptomic data for SERPINA1-silenced HTR8/SVneo cells were deposited in the NCBI Gene Expression Omnibus [75] and are accessible at GEO Series accession number GSE165090.

Declarations

Ethics approval and consent to participate

Written informed consent was obtained from all individuals (or their guardians) who participated in this study. Study methods for placental proteomics were approved by the ethics committee of Oulu University Hospital (79/2003, 14/2010, and 73/2013). Study methods for the Danish WES data were approved by the University of Southern Denmark (NVK#1302824) and the University of Iowa (IRB#200608748).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1 PEDEGO Research Unit and Medical Research Center Oulu, University of Oulu, PO Box 5000, 90014 Oulu, Finland. 2 Department of Children and Adolescents, Oulu University Hospital, 90014 Oulu, Finland. 3 Division of Human Genetics, Center for Prevention of Preterm Birth, Perinatal Institute, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, March of Dimes Prematurity Research Center Ohio Collaborative, Cincinnati, OH 45267, USA. 4 Proteomics and Mass Spectrometry Core Facilities, Biocenter Oulu, Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90014 Oulu, Finland. 5 Burroughs Wellcome Fund, Research Triangle Park, North Carolina 27709, USA. 6 Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.

Received: 17 January 2022 Accepted: 14 March 2022 Published online: 28 April 2022

References

1. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2006;371(9606):75–84.
2. Barfield WD. Public health implications of very preterm birth. Clin Perinatol. 2018;45(3):565–77.
3. Paredes SE, Knight AK, Smith AK. Insights into genetic susceptibility in the etiology of spontaneous preterm birth. Appl Clin Genet. 2015;8:283–90.
4. Zhang G, Srivastava A, Bacels J, Juodakos J, Jacobsson B, Muglia LJ. Genetic studies of gestational duration and preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:33–47.
5. Romero R, Dey SK, Fisher SJ. Preterm labor: one syndrome, many causes. Science. 2014;345(6198):760–5.
6. Saade GR, Boggess KA, Sullivan SA, Markenson GR, Iams JD, Coonrod DV, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. Am J Obstet Gynecol. 2016;214(5):633.e1–633.e24.
7. Oskovi Kaplan ZA, Ozgu-Erdinc AS. Prediction of preterm birth: maternal characteristics, ultrasound markers, and biomarkers: an updated overview. J Pregnancy. 2018;2018:8367571.
8. Lynch AM, Wagner BD, Deterding RR, Giclas PC, Gibbs RS, Janoff EN, et al. The relationship of circulating proteins in early pregnancy with preterm birth. Am J Obstet Gynecol. 2016;214(4):517.e1–8.
9. Buhimschi IA, Buhimschi CS. Proteomics of the amniotic fluid in assessment of the placenta. Relevance for preterm birth. Placenta. 2008;29 Suppl A:95.
10. Son M, Miller ES. Predicting preterm birth: cervical length and fetal fibronectin. Semin Perinatol. 2017;41(8):445–51.
11. Ville Y, Rozenberg P. Predictors of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:23–32.
12. BergHELLA V, SACcone G. Fetal fibronectin testing for reducing the risk of preterm birth. Cochrane Database Syst Rev. 2019;7:CD006843.
13. Gunko VO, Pogorelova TN, Linde VA. Proteomic profiling of the blood serum for prediction of premature delivery. Bull Exp Biol Med. 2016;161(6):829–32.
58. Rotondo JC, Oton-Gonzalez L, Selvatici R, Rizzo P, Pavasini R, Campo GC, et al. SERPINA1 gene promoter is differentially methylated in peripheral blood mononuclear cells of pregnant women. Front Cell Dev Biol. 2020;8:550543.

59. Tilg H, Vannier E, Vachino G, Dinarello CA, Mier JW. Anti-inflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med. 1993;178(5):1629–36.

60. Vanderpuye OA, Edwards HC, Booth AG. Proteins of the human placental microvillar cytoskeleton. alpha-Actinin. Biochem J. 1986;233(2):351–6.

61. King BF. The organization of actin filaments in human placental villi. J Ultrastruct Res. 1983;85(3):320–8.

62. Starodubtseva N, Nizyaeva N, Baev O, Bugrova A, Gapavae M, Muminova K, et al. SERPINA1 peptides in urine as a potential marker of preeclampsia severity. Int J Mol Sci. 2020;21(3). https://doi.org/10.3390/ijms21030914.

63. Ohmaru-Nakanishi T, Asoyama K, Fujikawa M, Fujita Y, Yagi H, Onoyama I, et al. Fibrosis in preeclamptic placentas is associated with stromal fibroblasts activated by the transforming growth factor-beta1 signaling pathway. Am J Pathol. 2018;188(3):683–95.

64. Boelte PY, Debray D, Guillot L, Corvol H, French CF. Modifier Gene Study Investigators. SERPINA1 Z allele is associated with cystic fibrosis liver disease. Genet Med. 2019;21(9):2151–5.

65. Mayhew TM, Barker BL. Villous trophoblast: morphometric perspectives on growth, differentiation, turnover and deposition of fibrin-type fibrinoid during gestation. Placenta. 2001;22(7):628–38.

66. Craven CM, Chedwick LR, Ward K. Placental basal plate formation is associated with fibrin deposition in decidual veins at sites of trophoblast cell invasion. Am J Obstet Gynecol. 2002;186(2):291–6.

67. Nizyaeva NV, Sukhacheva TV, Serov RA, Kulikova GV, Nagovitsyna MN, Kan NE, et al. Ultrastructural and immunohistochemical features of telocytes in placental villi in preeclampsia. Sci Rep. 2018;8(1):3453-w.

68. Stnrad R, McElvaney NG, Lomas DA. Alpha1-antitrypsin deficiency. N Engl J Med. 2020;382(15):1443–55.

69. Patel D, Teckman JH. Alpha-1-antitrypsin deficiency liver disease. Clin Liver Dis. 2018;22(4):643–55.

70. Zhang X, Pham K, Li D, Schutte RJ, Gonzalo DH, Zhang P, et al. A novel small molecule inhibits intrahepatocellular accumulation of Z-variant alpha 1-antitrypsin in vitro and in vivo. Cells. 2019;8(12). https://doi.org/10.3390/cells8121586.

71. Sandhaus RA. Alpha1-antitrypsin deficiency. 6: new and emerging treatments for alpha-1 antitrypsin deficiency-associated liver diseases. FEBS Lett. 2019;593(14):1849–62.

72. Sandhaus RA. Alpha1-antitrypsin deficiency. 6: new and emerging treatments for alpha1-antitrypsin deficiency. Thorax. 2004;59(10):904–9.

73. McCarthy C, Reeves ER, McElvaney NG. The role of neutrophils in alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(Suppl 4):297.

74. Lewis EC, Mizrahi M, Toledano M, Defelice N, Wright JL, Chung A, et al. Alpha1-antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A. 2008;105(42):16236–41.

75. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207–10.